Lisaftoclax to prevent complications in acute promyelocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a drug called lisaftoclax can prevent a serious complication (differentiation syndrome) in patients with acute promyelocytic leukemia (APL), a rare blood cancer. The goal is to make standard APL treatment safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 16 years old
- You have been diagnosed with acute promyelocytic leukemia (APL) confirmed by blood tests and genetic testing
- Your overall health status allows you to tolerate the study treatment (ECOG score 0–2, meaning you can do most daily activities)
- Your liver and kidney function are adequate to handle the study drugs (measured by blood tests)
- You can understand the study and sign a consent form agreeing to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
This trial tests a new drug, lisaftoclax, combined with azacytidine for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this combination can help control the disease better.
This trial tests if taking a combination of two medicines, Lisaftoclax and Azacitidine, after a stem cell transplant can help prevent acute myeloid leukemia (AML) from coming back in patients who have a high risk of relapse.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Hear when a new Acute Promyelocytic Leukemia (APL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.